Spectral power ratio as a measure of EEG changes in mild cognitive impairment 
due to Alzheimer’s disease: A case-control study

Flores-Sandoval, Aimee; Davila-Pérez, Paula; Buss, Stephanie S.; Donohoe, Kevin; O’Connor, Margaret; Shafi, Mouhsin M.; Pascual-Leone, Alvaro; Benwell, Christopher S.Y.; Fried, Peter J.

doi:10.1016/j.neurobiolaging.2023.05.010

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Spectral power ratio as a measure of EEG changes in mild cognitive impairment due to Alzheimer’s disease: A case-control study

MPS-Authors

/persons/resource/persons289768

Flores-Sandoval, Aimee
Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA;
Einstein Center for Neurosciences Berlin (ECN), Germany;
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Flores-Sandoval, A., Davila-Pérez, P., Buss, S. S., Donohoe, K., O’Connor, M., Shafi, M. M., et al. (2023). Spectral power ratio as a measure of EEG changes in mild cognitive impairment due to Alzheimer’s disease: A case-control study. Neurobiology of Aging. doi:10.1016/j.neurobiolaging.2023.05.010.

Cite as: https://hdl.handle.net/21.11116/0000-000D-33C2-E

Abstract

Adopting preventive strategies in individuals with subclinical Alzheimer’s disease (AD) has the potential to delay dementia onset and reduce health care costs. Thus, it is extremely important to identify inexpensive, scalable, sensitive, and specific markers to track disease progression. The electroencephalography spectral power ratio (SPR: the fast to slow spectral power ratio), a measure of the shift in power distribution from higher to lower frequencies, holds potential for aiding clinical practice. The SPR is altered in patients with AD, correlates with cognitive functions, and can be easily implemented in clinical settings. However, whether the SPR is sensitive to pathophysiological changes in the prodromal stage of AD is unclear. We explored the SPR of individuals diagnosed with amyloid-positive amnestic mild cognitive impairment (Aβ+aMCI) and its association with both cognitive function and amyloid load. The SPR was lower in Aβ+aMCI than in the cognitively unimpaired (CU) individuals and correlated with executive function scores but not with amyloid load. Hypothesis generating analyses suggested that aMCI participants with a lower SPR had an increased probability of a positive amyloid PET. Future research may explore the potential of this measure to classify aMCI individuals according to their AD biomarker status.